Compare Eli Lilly And Co (LLY) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Target Corporation — how do they compare? Eli Lilly And Co trades at $1,162.37 (market cap $1.02T), while Target Corporation trades at $138.36 (market cap $63.40B). The key difference: Eli Lilly And Co is far larger — about 16.1× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| LLY | TGT | |
|---|---|---|
Market Cap | $1.02T | $63.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $141.19 |
52-Week Low | $625.65 | $83.68 |
Enterprise Value | $1.06T | $78.70B |
Dividend Yield | 0.6% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Target (TGT) trades at $139.11, down 0.37% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 18.44, P/S of 0.6, and ROE of 22.02%, while revenue remains stable around $106 billion. Positive sentiment is driven by improved traffic trends and merchandising updates noted by Jefferies on July 15, 2026.
Target presents a balanced opportunity with strong profitability and analyst support, though risks include competitive retail pressures and margin volatility. The consensus price target of $137 suggests limited upside, but consistent dividend payments and operational cash flow near $7.4 billion provide stability. Execution on merchandising initiatives will be key for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
